Key statistics
On Friday, Tempest Therapeutics Inc (TPST:NAQ) closed at 6.30, 17.67% above the 52 week low of 5.35 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.63 |
---|---|
High | 6.69 |
Low | 6.25 |
Bid | 6.29 |
Offer | 6.35 |
Previous close | 6.66 |
Average volume | 62.04k |
---|---|
Shares outstanding | 3.92m |
Free float | 3.51m |
P/E (TTM) | -- |
Market cap | 26.18m USD |
EPS (TTM) | -18.38 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
- Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
- Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
- Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
- Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
- Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
- Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
- Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
- Tempest Reports Year End 2024 Financial Results and Provides Business Update
- Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
- FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
More ▼